All In Biotech

Drug Trial Radar · NCT06441578

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Special Drug Use Surveillance of ADZYNMA Intravenous 1500 (All-Case Investigation)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

May 30, 2024

Primary completion

Sep 30, 2032

Study completion Sep 30, 2032

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a survey in Japan of recombinant ADAMTS13 used to treat or to prevent participants with congenital thrombotic thrombocytopenic purpura (cTTP). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related from recombinant ADAMTS13 and to check if recombinant ADAMTS13 improves or prevents cTTP. During the study, participants with cTTP will take recombinant ADAMTS13 intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from recombinant ADAMTS13 for 18 months.

Conditions

  • Thrombotic Thrombocytopenic Purpura (TTP)

Interventions

  • Recombinant ADAMTS13Drug

    Recombinant ADAMTS13, Intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who Experience at Least One Treatment-Emergent Adverse Events (TEAE)Time frame: Up to 18 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Takeda Selected Site

    Tokyo, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.